Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 7:17:17562848241265776.
doi: 10.1177/17562848241265776. eCollection 2024.

Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

Bénédicte Caron  1   2   3   4 , Philippe Seksik  5 , Anthony Buisson  6 , Pauline Wils  7 , Guillaume Savoye  8 , Carmen Stefanescu  9   10 , David Laharie  11 , Lucas Guillo  12 , Vered Abitbol  13 , Joelle Bonnet  14 , Romain Altwegg  15 , Lucine Vuitton  16 , Driffa Moussata  17 , Arnaud Bourreille  18 , Amélie Biron  19 , Cyrielle Gilletta  20 , Mathurin Fumery  21 , Stephane Nahon  22 , Stephane Nancey  23 , Houda Camara  24 , Laurent Peyrin-Biroulet  25   26   3   4   27
Affiliations

Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

Bénédicte Caron et al. Therap Adv Gastroenterol. .

Abstract

Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown.

Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator.

Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale.

Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey's honest significant difference test.

Results: The most commonly used drugs at inclusion were Humira® (436/941, 46.3%), Amgevita® (177/941, 18.8%) and Hulio® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) (p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) (p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects.

Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.

Keywords: adalimumab; inflammatory bowel disease; preference; satisfaction.

PubMed Disclaimer

Conflict of interest statement

B. Caron reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly and Takeda. P. Seksik received consulting fees from Takeda, Abbvie, Merck-MSD, Biocodex, Janssen, Amgen, Astellas and Pfizer and grants from Biocodex and Janssen. A. Buisson declares consulting fees from Abbvie, Amgen, Arena, Biogen, Celltrion Healthcare, CTMA, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts; lecture fees for Abbvie, Amgen, Biogen, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma; research grants from Abbvie, Celltrion Healthcare Janssen, Lilly, Pfizer and Takeda. P. Wils declares lecture and/or consulting fees from Abbvie, Biogen, Celltrion Ferring, Janssen, Pfizer, Lilly, Takeda and Amgen. G. Savoye reports travel from Janssen. C. Stefanescu declares lecture and/or consulting fees from Abbvie, Amgen, Biogen, Celltrion Ferring, Gilead, Janssen, Pfizer, Lilly, Takeda, Tillots. D. Laharie declares counselling, boards, transports or fees from Abbvie, Amgen, Biogen, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Pfizer, Prometheus, Roche, Takeda. L. Guillo declares consulting fees for Abbvie. V. Abitbol has received lecture fees from Amgen, Biogen, Mylan, Sandoz, Pfizer, Takeda, Janssen, Tillots, Gilead, Ferring. J. Bonnet reports fees from Galapagos, Celltrion Healthcare and Fresenius Kabi. R. Altwegg declares counselling, boards, transports or fees from Abbvie, Amgen, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, Tillotts. L. Vuitton declares lecture and/or consulting fees from Abbvie, Amgen, Viatris, MSD, Ferring, Celltrion, Galapagos, Takeda, Pfizer, Janssen, Lilly, Dr Falk pharma. D. Moussata reports lecture and/or consulting fees from Abbvie, Amgen, Galapagos, Janssen, Takeda, Sanofi, Fuji, Cellvizio. A. Bourreille reports lecture and/or consulting fees from AbbVie, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, OSE Immunotherapeutics, Pfizer, Takeda, Tillots, Viatris. A. Biron reports no conflict of interest. C. Gilletta reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Galapagos, Janssen, Pfizer and Takeda. M. Fumery has participated in advisory boards and as an educational speaker (personal fees) for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, CTMA, Ferring, Fresenius, Galapagos, Janssen, MSD, Takeda, Tillotts, Pfizer, Sandoz and Viatris and has received research grants from Fresenius, Janssen and Pfizer. S. Nahon declares lecture and/or consulting fees from Abbvie, Amgen, Viatris, MSD, Ferring, Celltrion, Galapagos, Takeda, Pfizer, Janssen, Lilly, Ferring, Biogen. S. Nancey reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly, Takeda, Novartis and Pfizer. H. Camara declares no conflict of interest. L. Peyrin-Biroulet reports lecture and/or consulting fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant and Vectivbio.

Figures

Figure 1.
Figure 1.
Patients’ satisfaction with adalimumab. (a) Overall satisfaction with adalimumab; (b) Satisfaction about subcutaneous injection form; (c) Satisfaction about injection kit; (d) Satisfaction about support services.
See this image and copyright information in PMC

References

    1. Torres J, Bonovas S, Doherty G, et al.. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s Colitis 2020; 14(1): 4–22. - PubMed
    1. Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022; 16(1): 2–17. - PubMed
    1. EMA. Humira. European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/humira (2018, accessed September 23, 2023).
    1. EMA. Amgevita. European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita (2018, accessed September 23, 2023).
    1. EMA. Amsparity. European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity (2019, accessed September 23, 2023).

LinkOut - more resources